MAPT and Cognitive impairment: Instead, the aim now is to start Aβ immunotherapy at the onset of AD pathological changes, prior to or in the very early stages of clinical symptoms, in the hope of preventing downstream events, such as neuroinflammation and tau pathology, that lead to neuron loss and cognitive impairment.